Flebogamma 5% DIF


What it is used for

Replacement Therapy in: Primary immunodeficiency syndromes such as: congenital agammaglobulinaemia and hypogammaglobulinaemia, common variable immunodeficiency, severe combined immunodeficiency, Wiskott Aldrich Syndrome; Myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections; and children with congenital AIDS and recurrent infections. Immunomodulation: Idiopathic thrombocytopenia purpura (ITP), in children or adults at high risk of bleeding or prior to surgery to correct the platelet count, Guillian Barre syndrome. Allogenic bone marrow transplantation.


How to take it

The way to take this medicine is: Intravenous. This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.

  • Store below 30 degrees Celsius
  • Do not Freeze
  • Protect from Light
  • Shelf lifetime is 2 Years.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.


Reporting side effects

You can help ensure medicines are safe by reporting the side effects you experience.

You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems


How to take it

The way to take this medicine is: Intravenous. This medicine or fluids is given through a needle or tube (catheter) inserted into a vein.

  • Store below 30 degrees Celsius
  • Do not Freeze
  • Protect from Light
  • Shelf lifetime is 2 Years.

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.

Always read the label. If symptoms persist see your healthcare professional.


Do I need a prescription?

This medicine is available from a pharmacist and requires a prescription. It is Schedule 4 : Prescription Only Medicine.


Visual appearance

Clear or slightly opalescent, colourless or pale yellow solution

0 0 votes
Do you use this medicine? Rate it:
Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments